Identification of lactate-related subgroups and prognostic model in triple-negative breast cancer

被引:1
|
作者
Huang, Shan-Shan [1 ]
Wu, Lin-Yu [1 ]
Qiu, Yu [1 ]
Xie, Yi [1 ]
Wu, Hao [1 ]
Li, Ying-Qing [2 ]
Xie, Xin-Hua [1 ]
机构
[1] Sun Yat Sen Univ, Canc Ctr, Dept Breast Oncol, State Key Lab Oncol South China, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Outpatient Dept, State Key Lab Oncol South China, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China
基金
中国国家自然科学基金;
关键词
Triple-negative breast cancer; Lactate; Prognostic model; Nomogram; MUTATIONS; PEMBROLIZUMAB; CHEMOTHERAPY; METASTASES; FUMARATE; PREDICT;
D O I
10.1007/s00432-023-05171-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundTriple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that exhibits elevated glycolytic capacity. Lactate, as a byproduct of glycolysis, is considered a major oncometabolite that plays an important role in oncogenesis and remodeling of the tumor microenvironment. However, the potential roles of lactate in TNBC are not yet fully understood. In this study, our goal was to identify prognosis-related lactate genes (PLGs) and construct a lactate-related prognostic model (LRPM) for TNBC.MethodsFirst, we applied lactate-related genes to classify TNBC samples using a hierarchical clustering algorithm. Then, we performed the log-rank analysis and the least absolute shrinkage and selection operator analysis to screen PLGs and construct the LRPM. The biological functions of the identified PLGs in TNBC were investigated using CCK8 assay and clone formation assay. Finally, we constructed a nomogram based on the lactate-risk score and tumor clinical stage. We used the operating characteristic curve and decision curve analysis to evaluate the predictive capability of the nomogram.ResultsOur results showed that the TNBC samples could be classified into two subgroups with different survival probabilities. Three genes (NDUFAF3, CARS2 and FH), which can suppress TNBC cell proliferation, were identified as PLGs. Moreover, the LRPM and nomogram exhibited excellent predictive performance for TNBC patient prognosis.ConclusionWe have developed a novel LRPM that enables risk stratification and identification of poor molecular subtypes in TNBC patients, showing great potential in clinical practice.
引用
收藏
页码:13107 / 13122
页数:16
相关论文
共 50 条
  • [31] How can we refine the prognostic stratification of triple-negative breast cancer?
    Miglietta, Federica
    Dieci, Maria Vittoria
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (10) : 1045 - 1047
  • [32] Triple-negative breast cancer
    Stockmans, Gert
    Deraedt, Karen
    Wildiers, Hans
    Moerman, Philippe
    Paridaens, Robert
    CURRENT OPINION IN ONCOLOGY, 2008, 20 (06) : 614 - 620
  • [33] Identification of the pyroptosis-related prognostic gene signature and characterization of tumor microenvironment infiltration in triple-negative breast cancer
    Liu, Ji
    Ma, Jianli
    Zhang, Qingyuan
    FRONTIERS IN GENETICS, 2022, 13
  • [34] Identification of hypoxia-immune-related signatures for predicting immune efficacy in triple-negative breast cancer
    Wang, Luping
    Han, Haote
    Ma, Jiahui
    Feng, Yue
    Han, Zhuo
    Maharaj, Vinesh
    Tian, Jingkui
    Zhu, Wei
    Li, Shouxin
    Shao, Xiying
    ONCOLOGIE, 2024, 26 (03) : 433 - 444
  • [35] A prognostic model for triple-negative breast cancer patients with liver metastasis: A population-based study
    Zhang, Liguo
    Qiao, Zhen
    Yao, Yinsheng
    Li, Zhiqiang
    Hu, Lingzhi
    Mao, Yinyan
    Liu, Xiuling
    Chen, Weirong
    Zeng, Qing'an
    Zhao, Hong
    HELIYON, 2024, 10 (07)
  • [36] A Prognostic Risk Signature of Two Autophagy-Related Genes for Predicting Triple-Negative Breast Cancer Outcomes
    Yu, Bing
    Xing, Zhimei
    Tian, Xiaoxuan
    Feng, Rui
    BREAST CANCER-TARGETS AND THERAPY, 2024, 16 : 529 - 544
  • [37] Identification of circulating tumor cells marker genes as prognostic signature in triple-negative breast cancer
    Jia Hu
    Kai-Ming Zhang
    Xi Wang
    Discover Oncology, 16 (1)
  • [38] Atezolizumab for the treatment of triple-negative breast cancer
    Heimes, Anne-Sophie
    Schmidt, Marcus
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (01) : 1 - 5
  • [39] Understanding the biology of triple-negative breast cancer
    Criscitiello, C.
    Azim, H. A., Jr.
    Schouten, P. C.
    Linn, S. C.
    Sotiriou, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 13 - 18
  • [40] Role of Immunotherapy in Triple-Negative Breast Cancer
    Keenan, Tanya E.
    Tolaney, Sara M.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (04): : 479 - 489